Inflammatory-astrogliosis exacerbates damage in the injured spinal cord and limits repair. Here we identify Protease Activated Receptor 2 (PAR2) as an essential regulator of these events with mice lacking the PAR2 gene showing greater improvements in motor coordination and strength after compression-spinal cord injury (SCI) compared to wild type littermates. Molecular profiling of the injury epicenter, and spinal segments above and below, demonstrated that mice lacking PAR2 had significantly attenuated elevations in key hallmarks of astrogliosis (glial fibrillary acidic protein (GFAP), vimentin and neurocan) and in expression of proinflammatory cytokines (interleukin-6 (IL-6), tumor necrosis factor (TNF) and interleukin-1 beta (IL-1β)). SCI in PAR2 −/− mice was also accompanied by improved preservation of protein kinase C gamma (PKCγ)-immunopositive corticospinal axons and reductions in GFAP-immunoreactivity, expression of the proapoptotic marker BCL2-interacting mediator of cell death (BIM), and in signal transducer and activator of transcription 3 (STAT3). The potential mechanistic link between PAR2, STAT3 and astrogliosis was further investigated in primary astrocytes to reveal that the SCI-related serine protease, neurosin (kallikrein 6) promotes IL-6 secretion in a PAR2 and STAT3-dependent manner. Data point to a signaling circuit in primary astrocytes in which neurosin signaling at PAR2 promotes IL-6 secretion and canonical STAT3 signaling. IL-6 promotes expression of GFAP, vimentin, additional IL-6 and robust increases in both neurosin and PAR2, thereby driving the PAR2-signaling circuit forward. Given the significant reductions in astrogliosis and inflammation as well as superior neuromotor recovery observed in PAR2 knockout mice after SCI, we suggest that this receptor and its agonists represent new drug targets to foster neuromotor recovery.
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Introduction
Astrogliosis and inflammation are integrated contributors to the cascade of events occurring after spinal cord trauma. While certain components of this cascade worsen tissue damage and limit wound healing, other facets are essential to creating an environment favorable to repair. SCI-provoked astroglial and inflammatory responses fit on this complex continuum of injury and repair and this complicates targeted therapy. For example, the SCI-associated astroglial scar limits secondary damage by restricting inflammatory cell infiltration and providing mechanical support (Pekny et al., 1999; Okada et al., 2006; Herrmann et al., 2008; Wanner et al., 2013) . In addition however, reactive astrocytes along with microglia and infiltrating macrophages secrete pro-inflammatory cytokines that can injure sparred axons and oligodendroglia (Klusman and Schwab, 1997; Kim et al., 2001; Okada et al., 2004; Wang et al., 2005) . Moreover, the compact glial scar creates a chemical and physical barrier limiting regeneration of severed axons (Asher et al., 2001; Bradbury et al., 2002; Silver and Miller, 2004; Okada et al., 2006; Sofroniew, 2009) . A better understanding of the molecular underpinnings of inflammatory-astrogliosis in SCI may enable selective targeting to foster an environment ultimately conducive to wound healing and compatible with emerging regenerative interventions.
Protease Activated Receptor 2 (PAR2) is a G-protein coupled receptor (GPCR) playing fundamental roles in neural injury, including effects across neurons, astrocytes and neuroinflammatory responses (Luo et al., 2007) , although its activities in SCI are essentially unknown. There are four PARs (PARs1-4), each a classic seven transmembrane receptor. PARs are unique, being activated by cleavage within their extracellular domain to reveal a new amino-terminus that binds to the second extracellular loop to elicit intracellular signaling (Ramachandran et al., 2012) . 
